GlaxoSmithKline (GSK) AI Stock Analysis

GSK has won U.S. FDA approval for Hibsago (bepirovirsen), a first‑in‑class antisense oligonucleotide for adults with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy and without cirrhosis, marking a major advan...

GSK has secured U.S. FDA accelerated approval for its PD-1 inhibitor Jemperli as the first and only immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer, a biomarker-defined subset representing around five to ten p...

GSK has unveiled the first global clinical data for risvutatug rezetecan (Ris-Rez), a B7-H3-targeted antibody-drug conjugate, in relapsed extensive-stage small cell lung cancer, reporting a 61% objective response rate at the selected 8 mg/kg dose and...

GSK plc has disclosed that three senior executives acquired American Depositary Shares through automatic dividend reinvestment following the company’s October 8, 2026 shareholder dividend. The purchases, executed on October 13 on the New York S...

GSK has disclosed a series of routine transactions involving several senior executives, including the chief executive and chief financial officer, relating to ordinary shares and American depositary shares. The changes stem from the automatic reinves...

GSK has disclosed multiple transactions by senior management involving the automatic acquisition of ordinary shares via dividend reinvestment. Chief executive officer Luke Miels, Europe president Lynn Baxter, International president Mike Crichton and...

GSK plc has disclosed a series of share transactions involving several senior executives, including Chief Executive Officer Luke Miels and regional and functional presidents. The transactions consist of small acquisitions of ordinary shares on the Lo...

GSK has disclosed that independent non-executive director Wendy Becker has been appointed as a non-executive director of Tesco, effective 1 November 2026, in line with UK listing requirements for such announcements. The appointment underscores the cr...

GSK has admitted 19,352 new ordinary shares of 31¼ pence each to trading on the London Stock Exchange’s Main Market, bringing the total number of ordinary shares in issue to 4,316,311,662. The newly admitted shares, issued under the GlaxoS...

GSK plc has reported its latest share capital structure in line with UK Financial Conduct Authority transparency rules, confirming an issued share capital of 4,316,311,549 ordinary shares as of 30 September 2026. Of this total, 270,881,064 shares are...

GSK plc disclosed a transaction involving a person discharging managerial responsibilities, reflecting ongoing adherence to market transparency rules. The filing reports that Maya Martinez-Davis, President U.S., acquired a small number of notional Am...

Several GSK board members have purchased company securities, signalling additional personal investment in the biopharmaceutical group. Non-Executive Chair Sir Jonathan Symonds bought 1,500 ordinary shares on the London Stock Exchange on 18 September...

GSK has agreed to acquire a trispecific T cell-engager from Chimagen Biosciences for development in multiple myeloma, aiming to bring the programme into phase I trials in 2027 and secure full global rights under a deal worth up to $750 million. The d...

GSK and its licensor Hansoh Pharmaceutical reported phase III data from the ARTEMIS-008 trial in China showing that B7-H3-targeted antibody-drug conjugate risvutatug rezetecan (Ris-Rez) cut the risk of death by 54% versus topotecan in relapsed small...

GSK reported positive phase I/II data from its ARROS-1 trial of Jideytro (zidesamtinib) in tyrosine kinase inhibitor-naïve patients with advanced or metastatic ROS1-positive non-small cell lung cancer. The company plans a U.S. regulatory filing...

GSK plc has disclosed a series of small share acquisitions by several senior executives under its Share Reward Plan, reflecting routine participation in an established employee share ownership scheme. The transactions involve ordinary shares listed o...

GSK disclosed that Maya Martinez-Davis, the company’s President, US, has acquired notional American Depositary Shares in her GSK Executive Supplemental Savings Plan. The transaction, executed on 8 September 2026 on the New York Stock Exchange,...

GSK has granted a conditional share award to Chief People Officer and Executive Committee member Roanne Parry under its 2017 Performance Share Plan. The award, over 85,714 ordinary shares, forms part of the company’s performance-related incenti...

GSK has disclosed awards of ordinary shares to two senior figures under its 2025 Share Value Plan, reinforcing equity-based incentives at the top of the organisation. SVP and Company Secretary Victoria Whyte received 10,050 ordinary shares at £1...

GSK has updated the market on its capital structure, reporting that as of 31 August 2026 its issued share capital comprised 4,316,302,379 ordinary shares, including 270,881,064 shares held in treasury. After accounting for treasury shares, the total...

GSK reported positive phase II results for its investigational mRNA-based seasonal influenza vaccine, which targets both haemagglutinin and neuraminidase surface antigens of the virus. The candidate generated higher immune responses than standard-dos...

GSK disclosed that Maya Martinez-Davis, its President, US, acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan account. The transaction, involving a small volume of ADSs at a price of $51.78 per share, was...

GSK disclosed that Maya Martinez-Davis, its US president and a person discharging managerial responsibilities, sold a total of 3,916 American Depositary Shares on 20 August 2026 at an aggregate price of $52.14 per ADS on the New York Stock Exchange....

Japan’s Ministry of Health, Labour and Welfare has granted the first global approval for GSK’s Hibsago (bepirovirsen), an antisense oligonucleotide and the first functional cure for chronic hepatitis B in Japan. The drug is indicated for...

GSK said the US Food and Drug Administration has accepted a priority review of its supplemental biologics application for Jemperli in previously untreated stage II and III mismatch repair deficient or microsatellite instability-high locally advanced...

GSK disclosed several routine share transactions by senior executives involving the acquisition of American Depositary Shares through dividend reinvestment in company savings and supplemental plans. Non‑Executive Director Hal Barron, SVP and Gr...

GSK has disclosed a series of routine share dealings by several senior executives, including its CFO, regional presidents and other top managers, who each acquired 14 ordinary shares under the company’s Share Reward Plan. The purchases, all exe...

GSK plc disclosed a transaction involving Maya Martinez-Davis, its President for the U.S. business, who acquired notional American Depositary Shares through her GSK Executive Supplemental Savings Plan. The purchase, executed on 7 August 2026 on the N...

GSK has reported that as of 31 July 2026 its issued share capital comprised more than 4.3 billion ordinary shares, of which around 271 million are held in treasury, resulting in a total of 4.045 billion voting rights. The disclosure, made under UK Fi...